Ceragenix Pharmaceuticals
Ceragenix Pharmaceuticals was a biopharmaceutical company focused on the development and commercialization of novel anti-infective drugs based on its proprietary ceragenin technology. The company was headquartered in Denver, Colorado.
History[edit | edit source]
Ceragenix Pharmaceuticals was founded in 2005. The company aimed to address the growing problem of antibiotic resistance by developing new classes of anti-infective agents. Ceragenix's technology was based on ceragenins, which are synthetic antimicrobial peptides designed to mimic the body's natural defense mechanisms.
Technology[edit | edit source]
Ceragenix's core technology revolved around ceragenins, also known as cationic steroid antibiotics (CSAs). These compounds are designed to target and disrupt the membranes of bacteria, fungi, and viruses. Unlike traditional antibiotics, ceragenins are less likely to induce resistance due to their unique mechanism of action.
Ceragenins[edit | edit source]
Ceragenins are small, amphipathic molecules that mimic the structure and function of antimicrobial peptides (AMPs). They are composed of a steroidal backbone with cationic groups that interact with the negatively charged components of microbial membranes, leading to membrane disruption and cell death.
Products[edit | edit source]
Ceragenix Pharmaceuticals developed several products based on its ceragenin technology, including:
- CSA-13: A ceragenin compound with broad-spectrum antimicrobial activity.
- EpiCeram: A topical cream for the treatment of atopic dermatitis and other skin conditions. EpiCeram was designed to restore the skin's natural barrier function.
Research and Development[edit | edit source]
The company conducted extensive research and development to explore the potential applications of ceragenins in various medical fields. This included studies on their efficacy against methicillin-resistant Staphylococcus aureus (MRSA), Clostridium difficile, and other drug-resistant pathogens.
Acquisition and Legacy[edit | edit source]
In 2010, Ceragenix Pharmaceuticals was acquired by Cellerate, LLC, a company specializing in wound care products. The acquisition allowed for the continued development and commercialization of ceragenin-based products.
See also[edit | edit source]
- Antimicrobial resistance
- Biopharmaceutical
- Antimicrobial peptides
- Atopic dermatitis
- Methicillin-resistant Staphylococcus aureus
References[edit | edit source]
External links[edit | edit source]
 | This medical article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
